Aardvark Therapeutics IncAARD
ASignal's systematic analysis rates AARD as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on AARD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong liquidity position with current ratio of 12.63x
- Low debt-to-equity ratio of 0.01x indicating minimal leverage
- High cash reserves with total cash of $73.87M against $677,000 debt
- Price trading above 20-day and 50-day moving averages (SMA20: 6.72, SMA50: 5.70)
- Negative MACD histogram indicating weakening upward momentum
- Price below Bollinger middle band and declining price momentum
- Negative return on equity (-66.02%) and return on assets (-40.38%)
- Negative operating and free cash flows
- Negative forward P/E and EV/EBITDA suggesting unprofitable operations
- Zero gross, operating, and net margins
See the full verdict on AARD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AARD
Most investors never get a second opinion, let alone several. ASignal runs AARD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.